Synapse

← Clinical Pharmacology Advances and Applications

Papers in Clinical Pharmacology Advances and Applications

Page 3 · newest first

  1. Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatmentClinical Pharmacology Advances and Applications · 2019
  2. Assessing the effect of omega-3 fatty acid combined with vitamin D3 versus vitamin D3 alone on estradiol levels: a randomized, placebo-controlled trial in females with vitamin D deficiencyClinical Pharmacology Advances and Applications · 2019
  3. Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapyClinical Pharmacology Advances and Applications · 2019
  4. Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometryClinical Pharmacology Advances and Applications · 2019
  5. Treatment of acne with a combination of propolis, tea tree oil, and Aloe vera compared to erythromycin cream: two double-blind investigationsClinical Pharmacology Advances and Applications · 2018
  6. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjectsClinical Pharmacology Advances and Applications · 2018
  7. 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitusClinical Pharmacology Advances and Applications · 2018
  8. The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cellsClinical Pharmacology Advances and Applications · 2018
  9. Mechanisms and the clinical relevance of complex drug–drug interactionsClinical Pharmacology Advances and Applications · 2018
  10. Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxinClinical Pharmacology Advances and Applications · 2018
  11. A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspensionClinical Pharmacology Advances and Applications · 2018
  12. Distribution of pomalidomide into semen of healthy male subjects after multiple dosesClinical Pharmacology Advances and Applications · 2018
  13. Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indicationsClinical Pharmacology Advances and Applications · 2018
  14. Safinamide: an add-on treatment for managing Parkinson’s diseaseClinical Pharmacology Advances and Applications · 2018
  15. Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapyClinical Pharmacology Advances and Applications · 2018
  16. A review of the pharmacology and clinical efficacy of brivaracetamClinical Pharmacology Advances and Applications · 2018
  17. CRTH2 antagonists in asthma: current perspectivesClinical Pharmacology Advances and Applications · 2017
  18. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcomaClinical Pharmacology Advances and Applications · 2017
  19. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal functionClinical Pharmacology Advances and Applications · 2017
  20. Role of afatinib in the treatment of advanced lung squamous cell carcinomaClinical Pharmacology Advances and Applications · 2017
  21. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseasesClinical Pharmacology Advances and Applications · 2017
  22. Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacinClinical Pharmacology Advances and Applications · 2017
  23. NMDA receptors are important regulators of pancreatic cancer and are potential targets for treatmentClinical Pharmacology Advances and Applications · 2017
  24. Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective studyClinical Pharmacology Advances and Applications · 2017
  25. Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated falciparum malaria in pregnancy: a randomized open label studyClinical Pharmacology Advances and Applications · 2017
  26. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjectsClinical Pharmacology Advances and Applications · 2017
  27. Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigationsClinical Pharmacology Advances and Applications · 2017
  28. Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerationsClinical Pharmacology Advances and Applications · 2017
  29. Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteersClinical Pharmacology Advances and Applications · 2017
  30. A Phase I study evaluating the effect of age and weight on the pharmacokinetics of an injectable formulation of diclofenac solubilized with hydroxypropyl-β-cyclodextrinClinical Pharmacology Advances and Applications · 2016
  31. Skin models for the testing of transdermal drugsClinical Pharmacology Advances and Applications · 2016
  32. Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteersClinical Pharmacology Advances and Applications · 2016
  33. LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectivesClinical Pharmacology Advances and Applications · 2016
  34. Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjectsClinical Pharmacology Advances and Applications · 2016
  35. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesClinical Pharmacology Advances and Applications · 2016
  36. The effect of weight, body mass index, age, sex , and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysisClinical Pharmacology Advances and Applications · 2016
  37. Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillationClinical Pharmacology Advances and Applications · 2016
  38. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesClinical Pharmacology Advances and Applications · 2016
  39. Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary interventionClinical Pharmacology Advances and Applications · 2016
  40. Clinical use and applications of histone deacetylase inhibitors in multiple myelomaClinical Pharmacology Advances and Applications · 2016
  41. Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesClinical Pharmacology Advances and Applications · 2016
  42. Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infectionsClinical Pharmacology Advances and Applications · 2016
  43. Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsClinical Pharmacology Advances and Applications · 2015
  44. Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffnessClinical Pharmacology Advances and Applications · 2015
  45. Pharmacokinetics and skin-tissue penetration of daptomycin in ratsClinical Pharmacology Advances and Applications · 2015
  46. Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalinClinical Pharmacology Advances and Applications · 2015
  47. Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathwaysClinical Pharmacology Advances and Applications · 2015
  48. Carbon monoxide: a critical quantitative analysis and review of the extent and limitations of its second messenger functionClinical Pharmacology Advances and Applications · 2015
  49. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockersClinical Pharmacology Advances and Applications · 2015
  50. Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteersClinical Pharmacology Advances and Applications · 2015